SCHEMBL2487004

SCHEMBL2487004

COc1ccc(-c2ccccc2)cc1N=C=O

nearest known ligand 0.63

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HPGD P15428 4/20 0.63
ALDH1A1 P00352 3/20 0.63
TDP1 Q9NUW8 2/20 0.63
CYP3A4 P08684 1/20 0.63
KDM4E B2RXH2 3/20 0.41
MAPT P10636 3/20 0.41
ACLY P53396 4/20 0.41
KMT2A Q03164 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MEN1 O00255 2/20 0.40
POLB P06746 2/20 0.40
LMNA P02545 1/20 0.40
MAOB P27338 1/20 0.40
GAA P10253 1/20 0.40
PTPN1 P18031 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31243773 1.00 HPGD (0.63) HPGDALDH1A1TDP1CYP3A4KDM4E
SCHEMBL5891689 0.92 CYP3A4 (0.73) HPGDALDH1A1TDP1CYP3A4KDM4E
SCHEMBL28869830 0.87 ALDH1A1 (0.84) HPGDALDH1A1TDP1CYP3A4KDM4E
SCHEMBL1457356 0.84 L3MBTL1 (0.43) HPGDALDH1A1TDP1CYP3A4KDM4E
SCHEMBL27620107 0.79 CYP3A4 (0.50) HPGDALDH1A1TDP1CYP3A4KDM4E
SCHEMBL14992 0.78 CYP3A4 (1.00) HPGDALDH1A1TDP1CYP3A4KDM4E
SCHEMBL29350162 0.78 CYP3A4 (1.00) HPGDALDH1A1TDP1CYP3A4KDM4E
SCHEMBL29471398 0.77 ALDH1A1 (0.61) HPGDALDH1A1TDP1CYP3A4MAPT
SCHEMBL77114 0.77 ALDH1A1 (0.61) HPGDALDH1A1TDP1CYP3A4MAPT
SCHEMBL28427069 0.77 MAPT (0.51) HPGDALDH1A1TDP1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3774961-B1 ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS COVESTRO DEUTSCHLAND AG (DE) 2025-01-15 EP disclosed
US-20240150515-A1 Low Viscosity Catalyst Compositions for Producing Isocyanurate Polymers COVESTRO DEUTSCHLAND AG (DE) 2024-05-09 US disclosed
EP-4298140-A1 LOW VISCOSITY CATALYST COMPOSITIONS FOR PRODUCING ISOCYANURATE POLYMERS Covestro Deutschland AG (DE) 2024-01-03 EP disclosed
US-20220363809-A1 POLYMERIZABLE COMPOSITIONS FOR PREPARING POLYISOCYANURATE-BASED PLASTICS HAVING EXTENDED WORKLIFE COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) 2022-11-17 US disclosed
WO-2022179939-A1 LOW VISCOSITY CATALYST COMPOSITIONS FOR PRODUCING ISOCYANURATE POLYMERS COVESTRO DEUTSCHLAND AG (DE) 2022-09-01 WO disclosed
CN-114040934-A Polymerizable composition for producing polyisocyanurate-based plastics having extended pot life 科思创知识产权两合公司 2022-02-11 CN disclosed
US-20210238341-A1 ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS COVESTRO DEUTSCHLAND AG (DE) 2021-08-05 US disclosed
EP-3774961-A1 ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS Covestro Intellectual Property GmbH & Co. KG (DE) 2021-02-17 EP disclosed
CN-112020525-A Adducts of amine catalysts for making isocyanurate polymers 科思创知识产权两合公司 2020-12-01 CN disclosed
WO-2019197638-A1 ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS COVESTRO DEUTSCHLAND AG (DE) 2019-10-17 WO disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed
CN-101617036-A Benefit agent delivery compositions PROCTER & GAMBLE 2009-12-30 CN disclosed
EP-2111443-A2 BENEFIT AGENT DELIVERY COMPOSITIONS The Procter and Gamble Company (US) 2009-10-28 EP disclosed
US-20080200363-A1 Perfumes, brighteners, insect repellants, flavors, vitamins, fabric softeners, skin care agents; increasing potency, reducing cost PROECTER & GAMBLE COMPANY, THE 2008-08-21 US disclosed
WO-2008100601-A2 BENEFIT AGENT DELIVERY COMPOSITIONS THE PROCTER & GAMBLE COMPANY (US) 2008-08-21 WO disclosed
US-20080171783-A1 COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE MIGENIX INC. (CA) 2008-07-17 US disclosed
WO-2008080223-A1 COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE MIGENIX INC. (CA) 2008-07-10 WO disclosed
EP-1910279-A2 NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF MIGENIX INC. (CA) 2008-04-16 EP disclosed
US-20070021434-A1 NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF MIGENIX INC. (CA) 2007-01-25 US disclosed
WO-2007002639-A2 NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF MIGENIX INC. (CA) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238341-A1 ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS UNG, UGP2, AASDHPPT HPGD 1268/4885ALDH1A1 182/4885TDP1 925/4885
US-20070021434-A1 NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF HAVCR2, ADAR, NSUN2 HPGD 3355/4885ALDH1A1 1732/4885TDP1 2950/4885
US-20080171783-A1 COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE POLQ, POLI, POLH HPGD 866/4885ALDH1A1 2546/4885TDP1 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.